Angiotensin-converting enzyme inhibition after experimental myocardial infarct: Role of the kinin B1 and B2 receptors

Hypertension

Volumn 51, Issue 5, 2008, Pages 1352-1357

  Duka, Arvi ^a   Kintsurashvili, Ekaterina ^a   Duka, Irena ^a   Ona, Deborah ^a   Hopkins, Teresa A ^a   Bader, Michael ^b   Gavras, Irene ^a   Gavras, Haralambos ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

ACE inhibition; Bradykinin receptors; Cardioprotection; Gene knockout mice; Myocardial ischemia

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; BLOOD PRESSURE; CHYMASES; DISEASE MODELS, ANIMAL; HEART; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDYL-DIPEPTIDASE A; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

EID: 42349110618     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.108506     Document Type: Article

References (42)

1. Gavras H. Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
2. Erdos EG. The ACE and I: how ACE inhibitors came to be. FASEB. 2006;20:1034-1038.
3. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
4. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension. 1986;8:971-974.
5. Benetos A, Gavras I, Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986;8:1089-1092.
6. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke St, Breipohl G, König W, Knolle J, Schölkens BA. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
7. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
8. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993;21:996-1003.
9. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996;27:7-13.
10. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y, Kurumatani H, Kobayashi F, Kanmatsuse K, Kajiwara N. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 1994;23:450-455.
11. Kohlman O Jr, Neves Fde A, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension. 1995;25:1003-1007.
12. 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol. 1981;71:105-115.
13. 1 receptors for kinins. Pharmacol Rev. 1998;50:357-386.
14. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem. 1995;270:13706-13710.
15. 1 receptors. Proc Natl Acad Sci U S A. 2000;97:8140-8145.
16. 2-receptor gene. Circulation. 1997;96:3570-3578.
17. 2 receptor knockout mice. Biochem Biophys Res Commun. 1996;224:625-630.
18. 2 receptor gene. Hypertension. 1998;31:1278-1283.
19. 2 receptor null mice. Hypertension. 1999;34:176-180.
20. 1 bradykinin receptor in normotension and hypertension. Circ Res. 2001;88:275-281.
21. 2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997;30:735-740.
22. 2-kinin receptor knockout mice. Hypertension. 1999;34:563-567.
23. Emanueli C, Angioni GR, Anania V, Spissu A, Madeddu P. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene. J Hypertens. 1997;15:1701-1706.
24. 1 receptors of bradykinin. Hypertension. 2003;42:1021-1025.
25. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics. 2004;16:349-360.
26. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111-1115.
27. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension. 1996;28:1064-1069.
28. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 1999;277:H1967-H1974.
29. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
30. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, Liao TD, Yang JJ, Bader M, Yang XP. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension. 2005;45:747-753.
31. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res. 2001;88:1072-1079.
32. 2 receptor of bradykinin in insulin sensitivity. Hypertension. 2001;38:1355-1360.
33. Gavras I, Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Curr Opin Endocrinol Diabetes. 2002;9:323-328.
34. Lazar HL, Chipkin S, Philippides G, Bao Y, Apstein C. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann Thorac Surg. 2000;70:145-150.
35. Sugden MC, Holness MJ. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenasekinases. Arch Physiol Biochem. 2006;112:139-149.
36. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci. 1999;318:3-14.
37. Lagneux C, Bader M, Pesquero JB, Demenge P, Ribuot C. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol. 2002;2:815-822.
38. Tschope C, Heringer-Walther S, Koch M, Spillmann F, Wendorf M, Leitner E, Schultheiss HP, Walther T. Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol. 2000;129:1537-1538.
39. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol. 2000;86:913-918.
40. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-798.
41. Hoffmeister A, Rothenbacher D, Bazner U, Frohlich M, Brenner H, Hombach V, Koenig W. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol. 2001;87:262-266.
42. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension. 2002;40:653-659.